Clinical Trial Update: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome [Phase 3]

View source ↗

Summary

Long-term open-label extension study for subjects completing a Phase 3 trial of fesoterodine for overactive bladder (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Fesoterodine (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED